Regeneron Pharmaceuticals Inc (REGN)

Return on equity (ROE)

		Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Net income (ttm)	US$ in thousands	4,412,600	4,654,500	4,321,700	3,857,800	3,953,600	3,991,100	4,299,000	4,182,700	4,338,400	5,370,300	5,686,800	7,933,600	8,075,300	6,995,500	6,205,400	4,003,800	3,513,200	3,156,000	2,983,500	2,279,300
Total stockholders’ equity	US$ in thousands	29,353,600	29,325,900	28,205,800	26,991,100	25,973,100	24,904,400	24,017,900	23,495,200	22,664,000	21,438,800	20,687,800	19,914,700	18,768,800	17,258,000	15,127,300	11,977,000	11,025,300	10,125,500	9,057,400	12,133,000
ROE		15.03%	15.87%	15.32%	14.29%	15.22%	16.03%	17.90%	17.80%	19.14%	25.05%	27.49%	39.84%	43.03%	40.53%	41.02%	33.43%	31.86%	31.17%	32.94%	18.79%

December 31, 2024 calculation

ROE = Net income (ttm) ÷ Total stockholders’ equity
= $4,412,600K ÷ $29,353,600K
= 15.03%

Regeneron Pharmaceuticals Inc's Return on Equity (ROE) has shown fluctuations over the period from March 31, 2020, to December 31, 2024. The ROE, which reflects the company's ability to generate profit from its shareholders' equity, started at 18.79% in March 2020, steadily increased to a peak of 43.03% by December 2021, demonstrating efficient utilization of its shareholders' funds to generate profits.

However, from March 31, 2022, to December 31, 2024, the ROE witnessed a declining trend, reaching 15.03% by the end of 2024. This decline may indicate challenges in maintaining previous levels of profitability relative to shareholders' equity.

Additionally, the declining trend in ROE suggests that Regeneron Pharmaceuticals Inc may be facing challenges in improving its profitability and efficiency in utilizing its equity. It is essential for the company to analyze the factors contributing to this trend and consider strategies to enhance its ROE in the future.